GlassScriptPhysician profile
Elizabeth Lippner
NPI 1295179497
$1,577.50
in general payments reported to CMS, 2019-2025
9 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.82 · 2023: $1,098 · 2024: $134 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790 · Travel and Lodging: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.83 |
| Travel and Lodging | $765.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,062.55 | 2023 | |
| Blueprint Medicines Corporation | $114.37 | 2025 | Ayvakit |
| Amgen INC. | $89.30 | 2024-2025 | Actimmune |
| Csl Behring | $63.30 | 2024-2025 | Hizentra |
| Alk-Abello, INC | $54.85 | 2025 | |
| Grifols USA, LLC | $54.74 | 2021-2024 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $51.61 | 2025 | Neffy |
| Pharming Healthcare, INC. | $51.51 | 2025 | Ruconest |
| Regeneron Pharmaceuticals, INC. | $35.27 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lippner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.